zurück

Pertuzumab / trastuzumab (re-assessment: early breast cancer, HER2-positive, high risk of recurrence, adjuvant therapy, in combination with chemotherapy)

 

Subject:

  • Active Substance: Pertuzumab/trastuzumab
  • Name: Phesgo®
  • Therapeutic area: Breast cancer
  • Pharmaceutical company: Roche Pharma AG

 

Time table:

  • Start: 01.10.2022
  • Final decision by G-BA: 16.03.2023

 

Final decision:

  • Indication for a minor additional benefit